AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30554366
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment based on P. purpureum (PT) grass
Trial: 16496307
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (3 g, intravenously, n = 15)
Trial: 12492803
Drug: i.v. remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. remifentanil (1.5 micro g kg‐1, followed by 0.2 micro g kg‐1 min‐1)
Trial: 12492803
Drug: i.v. sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. sufentanil (0.2 micro g kg‐1 followed by 0.2 micro g kg‐1 h‐1)
Trial: 11736778
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of ropivacaine 0.1% and sufentanil 1 microg x ml(‐1) at a rate of 5‐9 ml x h(‐1)
Trial: 11736778
Drug: Intravenous patient‐controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient‐controlled analgesia using piritramide
Trial: 11736778
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of ropivacaine 0.1% and sufentanil 1 microg x ml(‐1)
Trial: 2879458
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of ipratropium bromide
Trial: 2879458
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg of fenoterol hydrobromide
Trial: 2879458
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of ipratropium plus 1.25 mg of fenoterol
Trial: 31757776
Drug: Online self-esteem
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Online self-esteem intervention (7 weekly sessions in Second Life)
Trial: 28619115
Drug: Intervention Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention Group (IG) - 120 min/week walking (396 METs/min/week) and monthly sociocultural gatherings
Trial: 20980335
Drug: Chemotherapy (temozolomide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (temozolomide or procarbazine/lomustine/vincristine)
Trial: 16582025
Drug: KRG-rootlets (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KRG-rootlets (6 g)
Trial: 16582025
Drug: KRG-rootlets (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KRG-rootlets (mean of 3 doses)
Trial: 31350122
Drug: Lisdexamfetamine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisdexamfetamine (6 weeks treatment)
Trial: 31350122
Drug: Placebo (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (6 weeks treatment)
Trial: 23254732
Drug: Dexamethasone cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone cyclophosphamide pulse (DCP) therapy
Trial: 19064982
Drug: Sunitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (50 mg/d for 4 weeks, 2 weeks off)
Trial: 2085986
Drug: Fosfomycin trometamol
RxNorm normalized name: trometamol
DrugBank: Tromethamine (DB03754)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosfomycin trometamol (3 g)
Trial: 7240438
Drug: Aspirin (3.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (3.25 Gm/day)
Trial: 27053264
Drug: Guidelines and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guidelines and prompts (G&P)
Trial: 19965822
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (IVB) plus low fluence photodynamic therapy (PDT)
Trial: 16062094
Drug: Fluphenazine (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluphenazine (12.5 mg/day)
Trial: 11853004
Drug: Irinotecan 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 120 mg/m2 on days 1 + 15 plus mitomycin C 8 mg/m2 on day 1
Trial: 11853004
Drug: Oxaliplatin 85
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 85 mg/m2 on days 1 + 15 plus mitomycin C 8 mg/m2 on day 1
Trial: 3109060
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose heparin (5000 IU twice daily)
Trial: 26552503
Drug: Thienopyridine (prasugrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thienopyridine (prasugrel 60 mg or clopidogrel 600 mg)
Trial: 25060833
Drug: Multimodal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal treatment program (MTP)
Trial: 25060833
Drug: Community care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community care (treatment-as-usual, TAU)
Trial: 18353909
Drug: Multilevel school-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multilevel school-based intervention; specific details on dosage and duration not available.
Trial: 18713888
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at 3 microg/mL
Trial: 18713888
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at 4.5 microg/mL
Trial: 18713888
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at 6 microg/mL
Trial: 10080585
Drug: 8 months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 months of chemotherapy with irradiation (XRT) of the primary site; 7 patients
Trial: 10080585
Drug: 8 months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 months of chemotherapy without XRT; 4 patients
Trial: 10080585
Drug: 9 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 9 weeks of chemotherapy without XRT; 20 patients
Trial: 6130329
Drug: Epoprostenol (prostacyclin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoprostenol (prostacyclin, PGI2) infusion at 7.5 ng/kg/min after the first hour for 5 hours, administered weekly for three weeks.
Trial: 6130329
Drug: Buffer infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffer infusion (control group) for 5 hours, administered weekly for three weeks.
Trial: 6130329
Drug: Epoprostenol (prostacyclin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoprostenol (prostacyclin, PGI2) infusion.
Trial: 31141195
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of antiretroviral treatment (ART) within 14 days
Trial: 31141195
Drug: Delayed initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Delayed initiation of antiretroviral treatment (ART) after nutritional recovery
Trial: 24786016
Drug: Single subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous (SC) injection of 12.5 mg rhTNFR-Fc
Trial: 24786016
Drug: Single subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous (SC) injection of 25 mg rhTNFR-Fc
Trial: 24786016
Drug: Single subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous (SC) injection of 50 mg rhTNFR-Fc
Trial: 24786016
Drug: Six SC
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six SC injections of 25 mg rhTNFR-Fc once every 3 days
Trial: 23006933
Drug: Sericin cream
RxNorm normalized name: sericin 1
DrugBank: Silk sericin (DB15531)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sericin cream
Trial: 23006933
Drug: Cream base
RxNorm normalized name: Cream Base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream base (placebo)
Trial: 20329659
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil (test formulation, 250 mg/5 mL suspension)
Trial: 20329659
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of cefuroxime axetil
Trial: 11899906
Drug: Various dose-fractionation
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various dose-fractionation schedules for palliative radiotherapy
Trial: 8553306
Drug: Prednisone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (1 mg/kg/day for 15 days and then tapering off)
Trial: 92589
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with lipocaine or trimecaine (antiarrhythmic drugs)
Trial: 30510079
Drug: Ravulizumab (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ravulizumab (900 mg every 8 weeks)
Trial: 30510079
Drug: Eculizumab (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab (900 mg every 2 weeks)
Trial: 28433518
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 20 mL
Trial: 17045903
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus training in physical counterpressure maneuvers (PCM)
Trial: 17045903
Drug: Standardized conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized conventional therapy alone
Trial: 15613917
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg aspartame (control test)
Trial: 10775738
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg oral micronized 17beta‐E2
Trial: 10775738
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg oral micronized 17beta‐E2
Trial: 10775738
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg oral micronized 17beta‐E2
Trial: 10775738
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oral micronized 17beta‐E2
Trial: 9369050
Drug: Midazolam 3
RxNorm normalized name: KETAMINE HYDROCHLORIDE 25 mg / MIDAZOLAM 3 mg / HYDROXYZINE HYDROCHLORIDE 10 mg SUBLINGUAL TROCHE [MKH Dose Pack]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 3 mg i.m.
Trial: 9369050
Drug: Clonidine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 0.15 mg orally
Trial: 9369050
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Atropine 0.5 mg i.m.)
Trial: 9369050
Drug: Hydroxyzine 25
RxNorm normalized name: hydroxyzine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine 25 mg i.m.
Trial: 3755561
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml 0.5% hyperbaric tetracaine
Trial: 3755561
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml 0.5% hyperbaric bupivacaine
Trial: 29864467
Drug: 40% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% hydrogen peroxide topical solution (HP40)
Trial: 22789134
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg of pumactant
Trial: 16607924
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment for 1 year
Trial: 15756212
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment for 1 year followed by a second year of GH
Trial: 10500313
Drug: Enoxaparin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (1 mg/kg/q12hr)
Trial: 10500313
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (target aPTT: 55‐85 sec)
Trial: 1825737
Drug: Ketoconazole (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (600 mg/day)
Trial: 22926599
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomoxetine (ATX) 0.5 mg/kg per day for 1 week, followed by 1.2 mg/kg per day for 7 weeks
Trial: 16860259
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + Pioglitazone (MET + PIO)
Trial: 15113713
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (2.8 g DHA/d)
Trial: 11355946
Drug: Standard-dose FEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose FEC (5 adjuvant courses of 5-FU, epirubicin, and cyclophosphamide)
Trial: 11355946
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with PBSCT (4 x FEC followed by high-dose cyclophosphamide, thiotepa, carboplatin, and autologous PBSCT)
Trial: 11355946
Drug: Both standard-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both standard-dose and high-dose chemotherapy
Trial: 11355946
Drug: Individual patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual patients post-treatment
Trial: 8172356
Drug: Immunotherapy (IT)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (IT) with a purified standardized preparation of Dermatophagoides farinae for 12 months
Trial: 2971185
Drug: RU 41740
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 41740 (two tablets per day for one week during the first month and one tablet per day for one week during the second and third months)
Trial: 16516598
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment for heart failure
Trial: 15281476
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation suspension (Pulmicort Respules)
Trial: 15281476
Drug: Reference treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference treatments
Trial: 16179595
Drug: Perindopril (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (8 mg)
Trial: 9818697
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily granisetron (1 mg i.v.) with dexamethasone (12 mg i.v.)
Trial: 9818697
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily granisetron (1 mg i.v.) with dexamethasone (12 mg i.v.)
Trial: 2527239
Drug: Farlutal (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Farlutal (500 mg MPA tablets, twice daily for 20 days)
Trial: 2527239
Drug: Clinovir (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinovir (500 mg MPA tablets, twice daily for 20 days)
Trial: 4624595
Drug: Disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate administered 20 minutes before exercise
Trial: 4624595
Drug: Disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate administered immediately before exercise
Trial: 4624595
Drug: Disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate administered at the end of exercise
Trial: 25928870
Drug: Nonspecific biofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonspecific biofeedback treatment
Trial: 24298764
Drug: Bloodletting therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bloodletting therapy at Jing‐well points
Trial: 24298764
Drug: Semen coicis
RxNorm normalized name: Hippocastani semen
DrugBank: Horse chestnut (DB13195)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semen coicis preparation
Trial: 24298764
Drug: Comprehensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive therapy (bloodletting therapy and semen coicis preparation)
Trial: 16685008
Drug: Albuterol pretreatment
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol pretreatment
Trial: 14993633
Drug: ROM (rifampin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ROM (rifampin 600 mg, ofloxacin 400 mg, minocycline 100 mg)
Trial: 14993633
Drug: MDT (rifampin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDT (rifampin 600 mg, clofazimine 300 mg, dapsone 100 mg, clofazimine 50 mg)
Trial: 11485587
Drug: Anti-tubercular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-tubercular treatment
Trial: 30484757
Drug: Maternal protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal protein intake in early pregnancy (g/d per kg)
Trial: 30484757
Drug: Maternal protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal protein intake from 6 months to 5 years (g/d per kg)
Trial: 28806537
Drug: Oral hydration
RxNorm normalized name: terpin hydrate Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hydration (2000 ml of water)
Trial: 28806537
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no more than 100 ml of water)
Trial: 21441125
Drug: Qa <650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qa <650 ml/min in distal fistulae
Trial: 21441125
Drug: Positive PE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive PE and Qa <900 ml/min in proximal fistulae
Trial: 18568520
Drug: N(2)O inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N(2)O inhalation (10 breaths of 50% N(2)O/50% O(2))
Trial: 12975669
Drug: gemcitabine/5‐fluorouracil (5FU)/leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine/5‐fluorouracil (5FU)/leucovorin combination
Trial: 11094000
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of isobaric bupivacaine (0.2%)
Trial: 11094000
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of isobaric ropivacaine (0.3%)
Trial: 1595337
Drug: Sublingual buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine in combination with rectally administered naproxen 1000 mg/24 h
Trial: 1595337
Drug: Sublingual buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine in combination with paracetamol 4000 mg/24 h
Trial: 1595337
Drug: Sublingual buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine as a sole agent
Trial: 31464192
Drug: Receipt of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receipt of weekly recommendations
Trial: 31464192
Drug: Coached treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coached treatment
Trial: 23917458
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid administered in 2 doses (1 hour preoperatively and 6 hours postoperatively)
Trial: 22464576
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (aspirin + low molecular weight heparin)
Trial: 22464576
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of conventional treatment and clopidogrel
Trial: 18327838
Drug: Pharmacological agents
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological agents for inducing hyperaemia during coronary physiology studies
Trial: 15899049
Drug: Risedronate 15
RxNorm normalized name: risedronate 150 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 15 mg
Trial: 15899049
Drug: Risedronate (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (both doses)
Trial: 3749616
Drug: Simultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous administration of salbutamol and beclomethasone dipropionate from a combination inhaler
Trial: 3749616
Drug: Sequential administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential administration of salbutamol and beclomethasone dipropionate from separate inhalers with an interval of 10 min
Trial: 29268667
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care plus regular visits from a therapy dog